ARPA-H Biomedical Research Agency Gets Funding Boost In US House Appropriations Bill
Executive Summary
Progress on appropriations follows passage of legislation in the House formally authorizing the new agency dedicated to advancing cutting edge research.
You may also be interested in...
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.
Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says
CMS will need to continue to be ‘savvy’ to strategies brand manufacturers already employ to shape the landscape for generic and biosimilar competition, policy expert says.